Skip to content

Press Releases

View:
 
Press Releases
All Releases
Jul 11, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announc...
Jun 26, 2013
PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the pricing of its ...
Jun 9, 2013
Plymouth, Mich., June 7, 2013 -- Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced positive top-line results from a Phase 2a clinical study...
May 2, 2013
LAKE BUENA VISTA, Fla., [May 2, 2013] -- Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announce...
Apr 26, 2013
ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced that it has comple...
Jan 7, 2013
Plymouth, MI [Jan 7, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy w...
Jan 4, 2013
PLYMOUTH, MI [Jan 4, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that Tim Mayleben has been named president and CEO of the company.  Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, wil...
Jan 3, 2013
PLYMOUTH, MI [Jan 3, 2013] - Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that company founder Roger Newton, Ph.D., will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Dr. Newton’s presentation will take place on Tues...
Apr 8, 2012
Plymouth, MI [April 8, 2012] – Esperion Therapeutics, Inc. today announced the appointment of Noah Rosenberg, MD, as its chief medical officer (CMO).  Dr. Rosenberg will lead the Esperion clinical advisory board and will develop and manage the company’s clinical programs.  He will also manage the regulatory review process f...
Mar 25, 2012
Plymouth, Michigan [March 25, 2012]- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002. This novel small molecule activator of AMP Kinase has demonstrated pre...
May 2, 2011
Plymouth, Michigan [May 2, 2011] - Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2...
Jan 6, 2011
Plymouth, Michigan [6 January 2011] - Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate. ETC-1002 is a novel small...
Jun 21, 2010
Plymouth, Michigan [June 21, 2010] - Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company&rs...
Jun 14, 2010
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to a...
Nov 15, 2009
Plymouth, Michigan [13 November 2009] - Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company’s novel small molecule compound designed...
= add release to Briefcase